SCHEMBL17169740

SCHEMBL17169740

O=C1CCC(NC(=O)c2ccccc2Br)C(=O)N1

nearest known ligand 0.72

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.72
DDB1 Q16531 4/20 0.67
IKZF3 Q9UKT9 1/20 0.56
BRD4 O60885 2/20 0.56
NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811963 0.85 CRBN (0.74) CRBNDDB1IKZF3BRD4NPC1
SCHEMBL4778728 0.85 CRBN (0.74) CRBNDDB1IKZF3BRD4
SCHEMBL29913668 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL17169744 0.84 CRBN (1.00) CRBNDDB1IKZF3BRD4
SCHEMBL29913697 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL23267776 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL29913826 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL20811955 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL20812183 0.84 CRBN (0.72) CRBNDDB1IKZF3BRD4
SCHEMBL29923298 0.84 CRBN (1.00) CRBNDDB1IKZF3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use YALE UNIVERSITY (US) 2023-12-05 US disclosed
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use YALE UNIVERSITY (US) 2023-12-05 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
WO-2018071606-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. (US) 2018-04-19 WO disclosed
US-20160058872-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2016-03-03 US disclosed
US-20150291562-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2015-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160058872-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N CRBN 1/4885DDB1 360/4885IKZF3 248/4885
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN CRBN 3/4885DDB1 750/4885IKZF3 3015/4885
US-20150291562-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N CRBN 1/4885DDB1 360/4885IKZF3 248/4885
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use CRBN, MDM2, UBE2N CRBN 1/4885DDB1 360/4885IKZF3 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.